Zenosense, Inc. (ZENO) Set to Help Healthcare Providers Contain MRSA-Related Treatment Costs
In the United States, treatment costs of hospitalized MRSA patients run as high as $4.2 billion per year. For a patient who has an MRSA infection, a hospital stay is likely to be three times longer than one by an uninfected patient, at three times the cost. An MRSA-infected patient is also five times more likely to die than an uninfected party. Zenosense, a healthcare technology company, is focused on developing a sensory device that detects MRSA bacterial contamination in patients. To that end, Zenosense has partnered with a respected sensor developer, Sgenia Group, to address this multibillion-dollar medical issue.…